Lung cancer is the most common type of cancer worldwide, accounting for 13% of the total number of new diagnosis and is classified according to histological type by the size and appearance of cells: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Given the prominence of lung cancer diagnosed in the population, predictive preclinical models are essential for treatment development. Patient derived xenograft (PDX) models are known to be the most predictive preclinical model and provide the most accurate approach to evaluating an agents efficacy prior to entering the clinic. CrownBio offers a large collection of over 300 well characterized lung cancer PDX models including 70 SCLC models, as well as primary and metastatic models. Learn more about these models in the following publications: More
-Molecular pathology of patient tumors, patient derived xenografts and cancer cell lines.pdf NSCLC harboring EGFR exon-20 insertions after the regulatory C-helix of kinase domain responds poorly to known EGFR inhibitors.pdf
EGF816 Exerts Anticancer Effects in Non-Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor.pdf
Patient-derived xenografts (PDX) offer the most translational preclinical model for efficacy screening in cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, PDX models reflect the heterogeneity and diversity of the human patient population. PDX give you an accurate, predictive model of how your treatment will perform, well before entering into expensive clinical trials.
CrownBio’s HuPrime® PDX collection well characterized for pathology, growth characteristics, and are also genetically/genomically annotated for gene expression, gene copy number, mutations, and fusions.